Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 7/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615969 | 1.00 | KMT2A (0.35) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL17915746 | 0.92 | KMT2A (0.37) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL17910244 | 0.92 | KMT2A (0.37) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL13231718 | 0.92 | KMT2A (0.37) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL15306068 | 0.90 | KMT2A (0.36) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL13231604 | 0.90 | KMT2A (0.38) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL27339979 | 0.84 | KMT2A (0.38) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL21105910 | 0.83 | — | — | |
| SCHEMBL13009242 | 0.83 | NPSR1 (0.39) | KMT2ACYP1A2CYP2D6MAPTMEN1 | |
| SCHEMBL13651503 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-05 | — | — | US | disclosed |
| EP-2112214-A1 | Dibenzo[g,p]chrysene derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090273278-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | KMT2A 3177/4885CYP1A2 426/4885CYP2D6 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.